In contrast to existing publications, these analyses were restricted to PET-staged localized PCA treated with curative intent (either surgery or radiotherapy ± ADT), i.e., patients without nodal or distant metastatic disease after PSMA-PET staging. This evidence concerns the gene FOLH1 and metastatic neoplasm.